Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for Residual/Recurrent CIN (TopIC-2)
NCT02669459Phase 3Unknown
- Sponsor
- Erasmus MC
- Start
- May 2016
- Primary completion
- Mar 2019
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of imiquimod in cervical intraepithelial neoplasia (CIN), sponsored by Erasmus MC. Status: unknown.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT02669459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669459.